Welcome to our dedicated page for PLUS THERAPEUTICS news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on PLUS THERAPEUTICS stock.
Plus Therapeutics reports news on its CNS oncology business, which combines precision diagnostics with targeted radiopharmaceutical development for central nervous system cancers. Recurring updates cover REYOBIQ™ (rhenium Re186 obisbemeda), a radiotherapeutic program for indications including leptomeningeal metastases and recurrent glioblastoma, as well as clinical and translational presentations, regulatory designations, manufacturing technology transfer and supply-chain partnerships.
The company’s news also covers the commercial expansion of CNSide®, including payer coverage, Medicare enrollment and reimbursement work for its cerebrospinal fluid assay platform. Corporate updates include leadership appointments, equity inducement grants under Nasdaq rules, financial results, capital actions and listing-compliance matters tied to its Nasdaq-traded common stock.
Cerenome (CNSY) entered a senior secured financing agreement with 3i Fund for a facility of up to $20 million with royalty-based repayments.
The company received an initial tranche at closing, with additional tranches contingent on achieving specified milestones. Proceeds are intended to support commercial scale-up and development of the CNSide cerebrospinal fluid assay platform and other proprietary laboratory-developed tests. Cerenome describes the structure as designed to be minimally dilutive to stockholders while funding CNSide sales growth and pipeline expansion. The company now forecasts its cash runway to extend well into 2028, based on this facility, other existing facilities, current cash, and expected CNSide-related sales and cash flow.
Cerenome (Nasdaq: CNSY) reported new data from two posters at the 2026 SNO/ASCO CNS Metastases Conference covering its REYOBIQ™ radiotherapeutic program and CNSide® diagnostics-driven care model for leptomeningeal metastases (LM).
Updated ReSPECT-LM and ongoing ReSPECT-LMM results showed pharmacokinetic, pharmacodynamic and dosimetry findings for REYOBIQ, including rapid cerebrospinal fluid (CSF) redistribution, a 1.7-hour ventricular half-life, apoptosis gene induction within about 5 hours, and no dose-limiting toxicities in Cohort 1a of the repeated-dosing study. A separate CNSide cost-of-care model estimated average LM treatment costs at about $119,550 per month and suggested a CNSide-enabled pathway could reduce monthly LM-related costs by roughly 33–47% under modeled scenarios.
Cerenome (Nasdaq: CNSY) reported second quarter 2026 results and a business update, including its rebranding from Plus Therapeutics effective August 3, 2026 and continued Nasdaq listing under ticker CNSY. The company advanced REYOBIQ clinical programs in leptomeningeal metastases (ReSPECT-LM), recurrent glioblastoma (ReSPECT-GBM) and pediatric brain cancer (ReSPECT-PBC), with no dose-limiting toxicities observed in ReSPECT-LM and first ReSPECT-PBC dosing expected in Q3 2026.
Cerenome’s CNSide CSF assay platform performed 232 tests in the first half of 2026, achieved contracted commercial payer coverage of 150 million lives by mid-year, obtained Medicare and AMA billing identifiers, and earned CAP accreditation. Cash, cash equivalents and investments totaled $8.6 million at June 30, 2026, unchanged from December 31, 2025.
Q2 2026 grant revenue was $0.4 million, operating loss $9.1 million and net loss $9.0 million, versus Q2 2025 net income of $5.2 million that included a $6.5 million favorable derivative fair value change.
Cerenome (Nasdaq:CNSY) announced that its subsidiary CNSide Diagnostics signed an in-network provider agreement with Health Care Service Corporation (HCSC), effective August 1, 2026, for the CNSide® cerebrospinal fluid Tumor Cell Enumeration assay. HCSC represents about 27.3 million commercial and Medicare Advantage covered lives.
Combined with prior contracts, CNSide now has contracted access to approximately 153 million covered lives, exceeding Cerenome’s full-year 2026 commercial and Medicare Advantage coverage objective of 150 million lives. According to Cerenome, CNSide’s clinical utility has been supported by 12 peer-reviewed publications, the FORESEE study, and over 11,000 tests performed at more than 120 U.S. cancer institutions since 2020.
Cerenome (Nasdaq: CNSY) announced that its wholly owned subsidiary, CNSide Diagnostics, has selected XiFin Empower RCM to provide billing and clearinghouse services for the CNSide cerebrospinal fluid assay platform. Cerenome expects to begin billing through XiFin in Q3 2026, including an accumulated backlog of CNSide tests.
According to Cerenome, XiFin’s AI-driven platform offers end-to-end revenue cycle capabilities and scalable automation to support higher test volumes without proportional administrative cost. The move follows expanded commercial and Medicare Advantage payer coverage for CNSide and is intended to help improve claim quality, reduce days sales outstanding, and support revenue and profitability goals.
Cerenome (Nasdaq: PSTV, transitioning to CNSY) announced completion of its corporate rebrand from Plus Therapeutics, effective August 3, 2026, when its name will become Cerenome and its stock will begin trading under ticker “CNSY” on the Nasdaq Capital Market.
The company positions itself as an integrated CNS oncology business combining precision diagnostics, targeted therapeutics and proprietary data. Key assets include the commercially available CNSide cerebrospinal fluid diagnostic, lead investigational radiotherapeutic REYOBIQ for multiple CNS cancers, and a data analytics/artificial intelligence platform, including a partnership with Ephemeral Technologies. Existing CNSide and REYOBIQ brands remain unchanged, and the name/ticker changes do not affect shareholder ownership.
Plus Therapeutics (Nasdaq: PSTV) will feature two scientific posters and a sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference, held August 13–15, 2026, in Boston. The presentations highlight the Company’s ReSPECT-LM clinical development program with rhenium obisbemeda and its CNSide® cerebrospinal fluid diagnostic platform.
Plus Therapeutics and wholly owned subsidiary CNSide Diagnostics will also host a one-hour symposium on August 13 titled “Redefining the Management of Leptomeningeal Metastases,” and plan to introduce the new Cerenome brand and expanded CNS cancer focus. Posters will later be posted on the Company’s website.
Plus Therapeutics (Nasdaq: PSTV), through its wholly owned subsidiary CNSide Diagnostics, signed a regional coverage agreement with Medical Mutual effective July 1, 2026. The agreement covers approximately 1.2 million people across Ohio and Kentucky for the CNSide® cerebrospinal fluid Tumor Cell Enumeration assay, increasing total contracted coverage to about 127 million people.
The CNSide® CSF Assay Platform is used for rapid diagnosis, treatment monitoring, and guidance in leptomeningeal metastases. According to Plus Therapeutics, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020, with reported sensitivity of 92%, specificity of 95%, and influence on treatment decisions in 90% of cases.
Plus Therapeutics (Nasdaq: PSTV) announced a collaboration with Genomic Testing Cooperative to integrate GTC next-generation sequencing into the CNSide cerebrospinal fluid assay. The partnership is expected to enable comprehensive DNA and RNA profiling across hundreds of biomarkers from a single CSF specimen, adding a guideline-recognized nucleic acid layer to CNSide’s established circulating tumor cell enumeration.
According to Plus Therapeutics, the move aligns CNSide with updated NCCN CNS Cancers Guidelines (Version 2.2026), supports its three-pillar CNS oncology strategy, and leverages GTC sequencing as a technical service to the CNSide CLIA lab. CNSide already holds AMA PLA code 0640U effective July 1, 2026, is enrolled with Medicare, and has commercial payer coverage of about 126 million U.S. lives. A health-economic analysis associated CNSide-enabled earlier LM management with roughly a 40% reduction in LM-related healthcare costs, and Plus cites an estimated U.S. LM addressable population above 100,000 patients annually.
Plus Therapeutics (Nasdaq: PSTV) highlighted an update to the NCCN CNS Cancers Guidelines that continues to endorse cerebrospinal fluid (CSF) analysis and recommends CSF cytology follow-up every 4–8 weeks for leptomeningeal metastases (LM) patients receiving intrathecal therapy, alongside MRI and clinical evaluation.
The company positioned its CNSide CSF assay as aligned with this framework, citing FORESEE study data where CNSide more than doubled LM tumor-detection sensitivity versus cytology in matched samples and previously reported health economics data suggesting ~40% LM-related cost reductions. In 2026, CNSide secured Medicare enrollment, CAP accreditation, expanded payer coverage including Blue Shield of California and Elevance Health, reaching about 126 million covered lives, with stated 2026 goals of 150 million covered lives and 1,250 total CNSide tests.